Prior Authorization Reform for Autoimmune and Blood Disorders Act
About This Bill
Committee
Latest Action · June 8, 2026
Referred to the Committee on Energy and Commerce, and in addition to the Committees on Education and Workforce, and Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
The Prior Authorization Reform for Autoimmune and Blood Disorders Act requires health insurance plans to cover drugs prescribed for autoimmune diseases, hemophilia, and Von Willebrand disease without restrictions based on whether they come from a pharmacy or another source. The bill also limits insurance companies' ability to require prior authorization for these drugs to once per year, unless the medication is typically used for 12 months or less, is an opioid, benzodiazepine, barbiturate, or carisoprodol, or requires special safety monitoring by the FDA. The legislation applies to all group health plans and individual health insurance policies offered by private insurers and would take effect for plan years beginning January 1, 2027. The bill affects millions of Americans with autoimmune and blood disorders by reducing barriers to accessing necessary medications and streamlining the insurance approval process.
Take Action
Your position
Add a comment
to comment on this bill.
Annotate the text
Highlight any passage on the Summary or Full Text tab to attach a note. Annotations appear on the Annotations tab.